GOLMePsA RCT early naive PsA Golimumab or PBO in addition to MTX+IM GCs No difference wk52 ACR20 GOL 76% PBO 55% MDA GOL 55% PBO 41% PBO arm received higher GC dose No new safety signal @RheumNow AbstOP0148 #EULAR2024 https://t.co/bj7YNXhssm

Nationwide epi study of lymphoproliferative disorders in Sjogren's. All pts in France! 4 % prevalence More in males and those with cryos and MGUS #EULAR2024 @rheumnow abst#OP0207 https://t.co/bEaWpTD7x3

Severe refractory Sjogrens - not in RCTs but some meds such as CD20 - Obinutuzumab, CART have been reported. A summary of slides @RheumNow https://t.co/9HQRAj3rzt

CD40 and CD40L (CD154) inhibition CD-40 monoclonal antibody CD 40 Ligand blockade- Dazodalibep @RheumNow https://t.co/n9CcrujVwa

#EULAR2024 POS0237 RNA-seq of muscle biopsy in inflammatory myopathy (IIM) showed distinct gene expressions underlying muscle damage between DM, Antisynthetase & PM. Potential targets for future therapeutics @RheumNow @IzukaShinji https://t.co/nf0pp2RhaE

Current and future treatment in Sjogrens Syndrome @rheumnow #EULAR2024 Many failed trails - likely secondary to non validated outcomes. 3 major domains - sicca, extraglandular manifestations, constitutional https://t.co/cCYX1YCqG2

"T and B cells playing tennis" In Sjogren's Syndrome! Thomas Dorner - #EULAR2024 @rheumnow https://t.co/Lum0A9cY9U

Isolated ⬆️ serum #IgG4 level: 💎💎💎 (Dr. Stone): ❓How high? >5x ULN ➡️PPV 75%‼️ ❓Typical organ(s) involved? ❓Another explanation? #eular2024 #rheumx @eular_org @RheumNow https://t.co/pm6wjvi2Vt

Different clusters - subpopulations of Sjogrens syndrome may exist and getting patient input is important @RheumNow https://t.co/7v5MYzzotT

How to assess treatment in Sjogren's Syndrome #EULAR2024 @RheumNow 1) define the target population 2) standardize inclusion criteria 3) Restricting ESSDAI domain to 5 domains 4) Correct endpoint choice https://t.co/m7DvZdpuZa

#EULAR2024 POS0223 UK multicentre data showed real-world avacopan use in #vasculitis differed from RCT: it was started later;often combined w other IS; GC tapering varied; 20% had eGFR<15. Compared to historical cohort of GC taper, OR of clinical response in AVA was 3.6 @RheumNow https://t.co/MP3OrRSJ0U